NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY

Abstract

Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires consideration of special clinical situations that predispose to an increased risk of bleeding.

Keywords

• anticoagulants
• atrial fibrillation
• prevention of thromboembolism
• warfarin
• dabigatran
• rivaroxaban
• apixaban